Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering

Reuters11-13

Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering

Xenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2583593734?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583593734","market":"nz","top_or_hot":-1,"title":"Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/XBIOW\">Xenetic Biosciences, Inc.</a> announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-13 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/XBIOW\">Xenetic Biosciences, Inc.</a> announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/XBIO\">Xenetic Biosciences Inc</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL8mrjgp:1","article_id":"2583593734","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583593734","pubTimestamp":1763041561,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Xenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","XBIO":"Xenetic Biosciences Inc"},"translate_title":"Xenetic Biosciences报告第三季度收入增加并完成390万美元的发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBIO":0.9},"content_text":"Xenetic Biosciences Reports Higher Q3 Revenue and Closes $3.9 Million Offering\n    \n\nXenetic Biosciences, Inc. announced its financial results for the third quarter of 2025, reporting a revenue increase of approximately $0.4 million, or 67.2%, to about $1.0 million compared to $0.6 million in the same period of 2024. The revenue growth was attributed to increased royalty revenue from the company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd., primarily due to royalties recognized from certain countries during the third quarter of 2025. The company ended the quarter with approximately $4.1 million in cash. Following the quarter's end, Xenetic completed an underwritten public offering, securing net proceeds of approximately $3.9 million. The company continues to advance its systemic DNase I program in combination with established cancer therapies and maintains ongoing collaborations and exploratory studies with institutional partners.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1101771) on November 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2583593734","isCrawlerRequest":true}